Bayer’s Executive Vice President and Head of Leaps, Juergen Eckhardt, has praised China’s burgeoning innovation landscape, highlighting its significant impact on the global healthcare sector.
In an exclusive interview with CGTN, Eckhardt emphasized that China has always been a pivotal market for the Fortune 500 company. “We have witnessed a remarkable surge in innovations emerging from China in recent years,” he stated. “These developments are not only transforming the local industry but also offering valuable insights that we can leverage to serve patients around the world.”
Bayer, a global leader in life sciences, has been actively engaging with China’s dynamic ecosystem to foster collaboration and accelerate the development of cutting-edge healthcare solutions. Eckhardt noted that the company’s commitment to China is driven by the country’s rapid advancements in technology and research. “The innovation we see here is truly inspiring,” he said. “It propels us to push boundaries and develop novel treatments that address unmet medical needs globally.”
The executive highlighted several areas where China’s innovation is making a significant difference, including biotechnology, digital health, and precision medicine. “Collaboration with Chinese partners allows us to integrate diverse perspectives and expertise, ultimately enhancing our ability to deliver impactful healthcare solutions,” Eckhardt explained.
Looking ahead, Bayer plans to deepen its engagement in China, investing in local talent and forging stronger partnerships with research institutions and startups. “Our goal is to build upon the innovative spirit we see in the Chinese mainland,” Eckhardt concluded. “By doing so, we can better serve patients everywhere and contribute to the advancement of global healthcare.”
Reference(s):
cgtn.com
